Rikoon Group LLC Sells 100 Shares of Celgene Co. (NASDAQ:CELG)

Rikoon Group LLC trimmed its holdings in shares of Celgene Co. (NASDAQ:CELG) by 4.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,174 shares of the biopharmaceutical company’s stock after selling 100 shares during the quarter. Rikoon Group LLC’s holdings in Celgene were worth $216,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in CELG. First PREMIER Bank acquired a new stake in shares of Celgene during the third quarter worth about $26,000. Liberty Wealth Management LLC lifted its holdings in Celgene by 212.8% in the second quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 200 shares during the period. B & T Capital Management DBA Alpha Capital Management acquired a new position in Celgene in the third quarter valued at approximately $28,000. Massey Quick Simon & CO. LLC acquired a new position in Celgene in the second quarter valued at approximately $33,000. Finally, Lenox Wealth Advisors LLC acquired a new position in Celgene in the third quarter valued at approximately $37,000. Hedge funds and other institutional investors own 72.31% of the company’s stock.

Shares of CELG traded up $0.54 during trading hours on Friday, hitting $109.54. 5,706,800 shares of the stock were exchanged, compared to its average volume of 6,764,924. The stock’s 50-day moving average price is $102.54 and its two-hundred day moving average price is $96.76. Celgene Co. has a 12-month low of $58.59 and a 12-month high of $109.75. The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.80 and a current ratio of 2.89. The company has a market cap of $76.64 billion, a price-to-earnings ratio of 14.39, a price-to-earnings-growth ratio of 0.51 and a beta of 1.41.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $2.99 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.70 by $0.29. Celgene had a return on equity of 78.15% and a net margin of 34.63%. The firm had revenue of $4.52 billion for the quarter, compared to analyst estimates of $4.39 billion. During the same quarter in the prior year, the company earned $2.29 EPS. Celgene’s revenue was up 16.1% on a year-over-year basis. On average, research analysts expect that Celgene Co. will post 10.7 earnings per share for the current year.

In related news, insider Terrie Curran sold 11,338 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the transaction, the insider now owns 13,493 shares of the company’s stock, valued at approximately $1,325,957.11. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.39% of the stock is currently owned by corporate insiders.

A number of analysts have recently commented on the company. Mizuho restated a “hold” rating and issued a $100.00 price objective on shares of Celgene in a research report on Sunday, October 20th. ValuEngine cut Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 1st. Standpoint Research cut Celgene from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Robert W. Baird cut Celgene from an “outperform” rating to a “neutral” rating and set a $101.00 price objective for the company. in a research report on Friday, November 1st. Finally, Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective for the company in a research report on Tuesday, July 23rd. One research analyst has rated the stock with a sell rating, nineteen have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $97.31.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: How a Strangle Strategy is different from a Straddle Strategy

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.